Zhejiang Cancer Hospital

🇨🇳China
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.zchospital.com
Clinical Trials
Related News

3D Printed Models for Liver Surgery

First Posted Date
2023-08-23
Last Posted Date
2023-09-21
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
5
Registration Number
NCT06006338
Locations
🇨🇳

1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou, Zhejiang, China

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

First Posted Date
2023-08-15
Last Posted Date
2023-09-21
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
48
Registration Number
NCT05992597
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

Recruiting
Conditions
Gastric Cancer
Healthy
Interventions
Other: No intervention
First Posted Date
2023-08-15
Last Posted Date
2023-08-15
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
1100
Registration Number
NCT05991947
Locations
🇨🇳

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics

First Posted Date
2023-08-14
Last Posted Date
2023-08-14
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
300
Registration Number
NCT05985577
Locations
🇨🇳

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Phase 2
Recruiting
Conditions
Double Hit Lymphoma
Triple Hit Lymphoma
Interventions
Drug: Selinexor+RCHOP
First Posted Date
2023-08-03
Last Posted Date
2023-08-03
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
10
Registration Number
NCT05974085
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhenjiang, China

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

First Posted Date
2023-08-02
Last Posted Date
2023-08-02
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
27
Registration Number
NCT05971199
Locations
🇨🇳

Guoliang Shao, Hangzhou, Zhejiang, China

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

Not Applicable
Not yet recruiting
Conditions
Advanced Colorectal Cancer
Interventions
Drug: Cetuximab Dabrafenib Tislelizumab
First Posted Date
2023-07-27
Last Posted Date
2023-07-27
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
22
Registration Number
NCT05963087
Locations
🇨🇳

Zhejiang Cancer Institute & Hospital, Hangzhou, Zhejing, China

Advanced Pancreatic Cancer

Phase 2
Not yet recruiting
Conditions
Progression-free Survival
Interventions
Drug: Sovalteinib Solutumab Tegeo
First Posted Date
2023-07-25
Last Posted Date
2023-07-25
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
30
Registration Number
NCT05958849

Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

Not Applicable
Not yet recruiting
Conditions
Advanced Colorectal Cancer
Interventions
Drug: Fruquintinib Combined With Chemotherapy
First Posted Date
2023-07-03
Last Posted Date
2023-07-20
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
72
Registration Number
NCT05928312
Locations
🇨🇳

Zhejiang Cancer Institute & Hospital, Hangzhou, Zhejing, China

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

First Posted Date
2023-06-27
Last Posted Date
2023-09-13
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
35
Registration Number
NCT05920863
Locations
🇨🇳

1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy